August 2021: The Food and Drug Administration has approved asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze, Jazz Pharmaceuticals, Inc.) as part of a multi-agent chemotherapeutic regimen for the treatment of acute lym..
August 2021: The FDA approved avapritinib (AyvakitTM, Blueprint Medicines Corp.) for adult patients with advanced systemic mastocytosis (AdvSM), which includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with an ..
Iúil 2021: Tá Breyanzi (Lisocabtagene maraleucel; liso-cel), cóireáil cille T nua receptor antaigin chimeric-treoraithe CD19 (CAR) arna fhorbairt ag Bristol Myers Squibb (BMS), ceadaithe ag Riarachán Bia agus Drugaí na SA (SAM).
Toisc go bhfuil aicmiú leoicéime agus srathú prognóis casta, níl aon mhodh cóireála amháin ann a oireann do chách, agus is gá aicmiú cúramach agus srathú prognóis a chur le chéile chun cóireáil a fhoirmiú lch.
Tá súil ag Eddle agus Pearlie Saddler, mar a bhfuil súil ag a bhean Pearlie, “taitneamh a bhaint as an saol rialta” ina mbaile i Carolina Theas. Nuair a luigh siad, chuaigh Saddlers go deonach agus ghlac siad páirt sa tseirbhís san eaglais. "Téimid ann go minic, go háirithe Eddi ..
Dúirt staidéar nua ó Ollscoil McMaster i gCeanada go bhfuil straitéis chóireála nua aimsithe aici le haghaidh leoicéime géarmhíochaine myeloid. Trí tháirgeadh cealla saille sa smior a spreagadh agus an microenvir smeara a choigeartú.
Is coscóir tyrosine kinase (BTK) den dara glúin é Acalabrutinib, druga níos nuaí a fhéadann marthanacht leoicéime lymphocytic ainsealach (CLL) agus linfóma cille maintlín (MCL) a fheabhsú. Creideann na taighdeoirí go ndéanann coscairí BTK cíor.
A study conducted at the Los Angeles Children ’s Hospital is providing the best treatment for a rare invasive leukemia called mixed phenotype acute leukemia (MPAL).This study (a 20-year quantitative synthesis of the scientific l..
According to the results of a 5-year follow-up of the key PACE trial published in the Journal of Hematology, panatinib (Ponatinib, Iclusig) has maintained long-lasting in severely treated patients with chronic phase chronic myeloi..
New Cleveland Clinic research shows for the first time that FDA-approved ibrutinib (ibrutinib) for lymphoma and leukemia may also help treat the most common and deadly brain tumors, and may one day be used in patients with gliobla..